R T Silver

Summary

Affiliation: Cornell University
Country: USA

Publications

  1. doi request reprint Interferon and the treatment of polycythemia vera, essential thrombocythemia and myelofibrosis
    Richard T Silver
    Myeloproliferative Disease Center, Division of Hematology Oncology, Weill Cornell Medical Center, New York, NY, USA
    Expert Rev Hematol 6:49-58. 2013
  2. doi request reprint Treatment of polycythemia vera with imatinib mesylate
    Richard T Silver
    Division of Hematology and Medical Oncology, Department of Medicine, Weill Cornell Medical College, New York, NY 10065 4896, USA
    Leuk Res 36:156-62. 2012
  3. ncbi request reprint Long-term effects of the treatment of polycythemia vera with recombinant interferon-alpha
    Richard T Silver
    Division of Hematology Oncology, Department of Medicine, Weill Medical College of Cornell University, New York, New York 10021, USA
    Cancer 107:451-8. 2006
  4. ncbi request reprint The third International Congress on Myeloproliferative and Myelodysplastic Syndromes
    R T Silver
    Weill Medical College of Cornell University, 1300 York Ave Box 581, New York, NY 10021 4896, USA
    Leuk Res 31:11-7. 2007
  5. ncbi request reprint Treatment of the chronic phase of chronic myeloid leukemia with an intermittent schedule of recombinant interferon alfa-2b and cytarabine: results from CALGB study 9013
    Richard T Silver
    Weill Medical College of Cornell University, Division of Hematology Oncology, 525 E 68th St Box 581, New York, NY 10021, USA
    Leuk Lymphoma 44:39-48. 2003
  6. ncbi request reprint Chronic myeloid leukemia
    Richard T Silver
    Weill Cornell Medical College, 525 East 68th Street, Box 581, New York, NY 10021, USA
    Hematol Oncol Clin North Am 17:1159-73, vi-vii. 2003
  7. doi request reprint Update on the treatment of polycythemia vera with recombinant interferon alfa or imatinib mesylate
    Richard T Silver
    New York Presbyterian Hospital Weill Cornell Medical Center, 1300 York Avenue, Box 581, New York, NY 10021, USA
    Curr Hematol Malig Rep 2:43-6. 2007
  8. pmc JAK2(V617F) allele burden in polycythemia vera correlates with grade of myelofibrosis, but is not substantially affected by therapy
    Richard T Silver
    Division of Hematology and Medical Oncology, Department of Medicine, Weill Cornell Medical College, New York, NY 10065 4896, USA
    Leuk Res 35:177-82. 2011
  9. pmc Predictive value of in vitro mutation data to guide second-generation tyrosine kinase inhibitor selection: ready for prime time?
    Richard T Silver
    Weill Cornell Medical College, Department of Medicine, Division of Hematology and Medical Oncology, New York, New York 10065 4896, USA
    Oncologist 16:554-8. 2011
  10. doi request reprint Recombinant interferon-α may retard progression of early primary myelofibrosis: a preliminary report
    Richard T Silver
    Division of Hematology and Medical Oncology, Department of Medicine, Weill Cornell Medical College, 1305 York Avenue, New York, NY 10021, USA
    Blood 117:6669-72. 2011

Detail Information

Publications43

  1. doi request reprint Interferon and the treatment of polycythemia vera, essential thrombocythemia and myelofibrosis
    Richard T Silver
    Myeloproliferative Disease Center, Division of Hematology Oncology, Weill Cornell Medical Center, New York, NY, USA
    Expert Rev Hematol 6:49-58. 2013
    ..In hypercellular primary myelofibrosis, rIFN-α has restored normal blood counts, reduced splenomegaly and induced morphologic marrow remissions. This article highlights our current use of rIFN-α in MPNs...
  2. doi request reprint Treatment of polycythemia vera with imatinib mesylate
    Richard T Silver
    Division of Hematology and Medical Oncology, Department of Medicine, Weill Cornell Medical College, New York, NY 10065 4896, USA
    Leuk Res 36:156-62. 2012
    ..Therefore, we believe there may be a role for IM in patients with these characteristics whose disease cannot be controlled by, or as an alternative to, other myelosuppressive treatments...
  3. ncbi request reprint Long-term effects of the treatment of polycythemia vera with recombinant interferon-alpha
    Richard T Silver
    Division of Hematology Oncology, Department of Medicine, Weill Medical College of Cornell University, New York, New York 10021, USA
    Cancer 107:451-8. 2006
    ..Evidence is presented indicating that rIFN alpha effectively reduces PHL requirements, thrombocythemia, splenomegaly, and thrombohemorrhagic events. It is an effective drug for treating PV with acceptable toxicity...
  4. ncbi request reprint The third International Congress on Myeloproliferative and Myelodysplastic Syndromes
    R T Silver
    Weill Medical College of Cornell University, 1300 York Ave Box 581, New York, NY 10021 4896, USA
    Leuk Res 31:11-7. 2007
    ..He reviewed the molecular steps in the formation of the Philadelphia chromosome and some of the newly described mutations leading to resistance to chemotherapy (see Section 4)...
  5. ncbi request reprint Treatment of the chronic phase of chronic myeloid leukemia with an intermittent schedule of recombinant interferon alfa-2b and cytarabine: results from CALGB study 9013
    Richard T Silver
    Weill Medical College of Cornell University, Division of Hematology Oncology, 525 E 68th St Box 581, New York, NY 10021, USA
    Leuk Lymphoma 44:39-48. 2003
    ..01) using a landmark analysis at 18 months. This intermittent schedule of rIFNalpha-2b/ara-C has a high response rate in patients with CML with acceptable toxicity...
  6. ncbi request reprint Chronic myeloid leukemia
    Richard T Silver
    Weill Cornell Medical College, 525 East 68th Street, Box 581, New York, NY 10021, USA
    Hematol Oncol Clin North Am 17:1159-73, vi-vii. 2003
    ....
  7. doi request reprint Update on the treatment of polycythemia vera with recombinant interferon alfa or imatinib mesylate
    Richard T Silver
    New York Presbyterian Hospital Weill Cornell Medical Center, 1300 York Avenue, Box 581, New York, NY 10021, USA
    Curr Hematol Malig Rep 2:43-6. 2007
    ..Used as single agents, each produces lasting remissions in about 75% of patients with polycythemia vera. Of significance, change in JAK2 expression has been reported after treatment with both agents...
  8. pmc JAK2(V617F) allele burden in polycythemia vera correlates with grade of myelofibrosis, but is not substantially affected by therapy
    Richard T Silver
    Division of Hematology and Medical Oncology, Department of Medicine, Weill Cornell Medical College, New York, NY 10065 4896, USA
    Leuk Res 35:177-82. 2011
    ..The JAK2(V617F) allele burden did not change significantly in treated patients with serial JAK2 analyses...
  9. pmc Predictive value of in vitro mutation data to guide second-generation tyrosine kinase inhibitor selection: ready for prime time?
    Richard T Silver
    Weill Cornell Medical College, Department of Medicine, Division of Hematology and Medical Oncology, New York, New York 10065 4896, USA
    Oncologist 16:554-8. 2011
    ..Selection of a second-generation tyrosine kinase inhibitor should therefore be based upon its toxicity profile in conjunction with the patient's comorbidities and the practitioner's experience...
  10. doi request reprint Recombinant interferon-α may retard progression of early primary myelofibrosis: a preliminary report
    Richard T Silver
    Division of Hematology and Medical Oncology, Department of Medicine, Weill Cornell Medical College, 1305 York Avenue, New York, NY 10021, USA
    Blood 117:6669-72. 2011
    ..Improvement in marrow morphology occurred in 4. Toxicity was acceptable. These results, with documented marrow reversion because of interferon treatment, warrant expanded evaluation...
  11. ncbi request reprint The second international congress on myeloproliferative and myelodysplastic syndromes
    R T Silver
    Weill Cornell Medical Center, 1300 York Ave Box 34, New York, NY 10021 4896, USA
    Leuk Res 28:979-85. 2004
    ....
  12. ncbi request reprint Examination of platelet function in whole blood under dynamic flow conditions with the cone and plate(let) analyzer: effect of erythrocytosis and thrombocytosis
    Ellinor I Peerschke
    Department of Pathology and Laboratory Medicine, Weill Medical College of Cornell University, New York, NY 11777, USA
    Am J Clin Pathol 127:422-8. 2007
    ..These studies suggest that CPA platelet deposition patterns may provide novel insight into global platelet function during hemodynamic flow...
  13. ncbi request reprint Treatment of polycythemia vera with recombinant interferon alpha (rIFNalpha) or imatinib mesylate
    Richard T Silver
    New York Presbyterian Weill Cornell Medical Center, 1300 York Avenue, Box 581, New York, NY 10021, USA
    Curr Hematol Rep 4:235-7. 2005
    ..Two new drugs are now available, interferon and imatinib mesylate, which may alter the course of this disease. Used as single agents, each produces lasting remissions in about 75% of the cases...
  14. ncbi request reprint Risk factors for severe neuropsychiatric toxicity in patients receiving interferon alfa-2b and low-dose cytarabine for chronic myelogenous leukemia: analysis of Cancer and Leukemia Group B 9013
    M L Hensley
    Memorial Sloan Kettering Cancer Center, Weill Medical College of Cornell University, and New York Presbyterian Hospital, New York, NY 10021, USA
    J Clin Oncol 18:1301-8. 2000
    ..The purpose of this study was to identify predictors for the development of severe neuropsychiatric toxicity in CML patients receiving rIFNalpha2b-based therapy...
  15. ncbi request reprint Efficacy and safety of gemtuzumab ozogamicin in patients with poor-prognosis acute myeloid leukemia
    G J Roboz
    Division of Hematology and Oncology, Weill Medical College of Cornell University and The New York Presbyterian Hospital, New York, NY 10021, USA
    Leuk Lymphoma 43:1951-5. 2002
    ..In conclusion, in patients with relapsed/refractory AML, gemtuzumab ozogamicin has a comparable response rate to single-agent chemotherapy and may offer a more favorable toxicity profile...
  16. doi request reprint The blast phase of chronic myeloid leukaemia
    Richard T Silver
    Department of Medicine, Division of Hematology and Medical Oncology, Leukemia and Myeloproliferative Center, Weill Cornell Medical College, 525 East 68th Street, Box 581, Payson Pavilion, 3rd Floor, New York, NY 10065, USA
    Best Pract Res Clin Haematol 22:387-94. 2009
    ..For those patients who achieve a remission following the use of one of the aforementioned drugs, bone marrow transplantation is recommended...
  17. ncbi request reprint A study of a reduced-intensity conditioning regimen followed by allogeneic stem cell transplantation for patients with hematologic malignancies using Campath-1H as part of a graft-versus-host disease strategy
    Tsiporah Shore
    Weill Medical College of Cornell University New York Presbyterian Hospital, New York, New York 10021, USA
    Biol Blood Marrow Transplant 12:868-75. 2006
    ....
  18. ncbi request reprint Treatment of polycythemia vera
    Richard T Silver
    Division of Hematology Oncology, New York Presbyterian Weill Cornell Medical Center, New York, New York 10021 4873, USA
    Semin Thromb Hemost 32:437-42. 2006
    ..Clearly, the best treatment for patients with PV is still sought. Perhaps more explicit exploitation of the JAK2 abnormality found in PV (and other myeloproliferative diseases) may provide more effective agents in the future...
  19. ncbi request reprint Ex vivo evaluation of erythrocytosis-enhanced platelet thrombus formation using the cone and plate(let) analyzer: effect of platelet antagonists
    Ellinor I B Peerschke
    Department of Pathology, Weill Medical College of Cornell University, New York, NY, USA
    Br J Haematol 127:195-203. 2004
    ..These findings support the use of CPA for ex vivo evaluation of the contribution of RBC to platelet function and its inhibition under physiological shear conditions...
  20. ncbi request reprint The emergence of Ph-, trisomy -8+ cells in patients with chronic myeloid leukemia treated with imatinib mesylate
    Eric Feldman
    The Leukemia and Myeloproliferative Center, Weill Medical College of Cornell University, New York, NY, USA
    Exp Hematol 31:702-7. 2003
    ..To describe clinical and laboratory features of a cohort of patients with chronic myelogenous leukemia (CML) who developed Ph(-), trisomy 8(+) metaphases while on treatment with imatinib mesylate...
  21. doi request reprint Intermittent target inhibition with dasatinib 100 mg once daily preserves efficacy and improves tolerability in imatinib-resistant and -intolerant chronic-phase chronic myeloid leukemia
    Neil P Shah
    Division of Hematology Oncology, University of California, San Francisco School of Medicine, Box 1270, 505 Parnassus Ave, San Francisco, CA 94143, USA
    J Clin Oncol 26:3204-12. 2008
    ..Once-daily treatment resulted in less toxicity, suggesting that toxicity results from continuous inhibition of unintended targets. Here, a dose- and schedule-optimization study is reported...
  22. ncbi request reprint Anagrelide is effective in treating patients with hydroxyurea-resistant thrombocytosis in patients with chronic myeloid leukemia
    R T Silver
    The Leukemia and Myeloproliferative Disease Center, Division of Hematology Oncology, Weill Medical College of Cornell University, 525 East 68th Street, New York, NY 10021, USA
    Leukemia 19:39-43. 2005
    ....
  23. ncbi request reprint Direct evidence that Bcr-Abl tyrosine kinase activity disrupts normal synergistic interactions between Kit ligand and cytokines in primary primitive progenitor cells
    Annabel Strife
    Molecular Pharmacology and Chemistry Program, Sloan Kettering Institute, New York, NY, USA
    Mol Cancer Res 1:176-85. 2003
    ....
  24. ncbi request reprint Polycythemia vera and other polycythemia syndromes
    Richard T Silver
    Weill Cornell Medical University, New York, NY, USA
    Cancer Treat Res 142:1-27. 2008
  25. ncbi request reprint Five-year follow-up of patients receiving imatinib for chronic myeloid leukemia
    Brian J Druker
    Oregon Health and Science University Cancer Institute, L592, 3181 SW Sam Jackson Park Rd, Portland, OR 97239, USA
    N Engl J Med 355:2408-17. 2006
    ..Imatinib inhibits this kinase, and in a short-term study was superior to interferon alfa plus cytarabine for newly diagnosed CML in the chronic phase. For 5 years, we followed patients with CML who received imatinib as initial therapy...
  26. ncbi request reprint A hope for the future
    Richard T Silver
    Cancer Invest 21:486. 2003
  27. ncbi request reprint Dasatinib induces notable hematologic and cytogenetic responses in chronic-phase chronic myeloid leukemia after failure of imatinib therapy
    Andreas Hochhaus
    III Medizinische Klinik, Medizinische Fakultat Mannheim, Universitat Heidelberg, Theodor Kutzer Ufer 1 3, 68167 Mannheim, Germany
    Blood 109:2303-9. 2007
    ..This trial was registered at www.clinicaltrials.gov as CA180013...
  28. pmc Novel tumor antigens elicit anti-tumor humoral immune reactions in a subset of patients with polycythemia vera
    Zeyu Xiong
    Department of Pharmacology, Temple University School of Medicine, Philadelphia, PA 19140, USA
    Clin Immunol 122:279-87. 2007
    ....
  29. ncbi request reprint Correlation of three methods of measuring cytogenetic response in chronic myelocytic leukemia
    Martin L Lesser
    North Shore Long Island Jewish Research Institute, Manhasset, NY, USA
    Cancer Genet Cytogenet 137:79-84. 2002
    ..The results indicate that mixing data of different methods to measure treatment response within or between patients may be misleading clinical index...
  30. ncbi request reprint Case 15-2006: the Budd-Chiari syndrome and V617F mutation in JAK2
    Jerry L Spivak
    N Engl J Med 355:737; author reply 738. 2006
  31. ncbi request reprint A phase 2 study of imatinib in patients with relapsed or refractory Philadelphia chromosome-positive acute lymphoid leukemias
    Oliver G Ottmann
    Medizinische Klinik III Abteilung Haematologie, Johann Wolfgang Goethe Universitat, 60590 Frankfurt, Germany
    Blood 100:1965-71. 2002
    ..Further studies are warranted to test the effects of imatinib in combination with other agents and to define the mechanisms of resistance to imatinib...
  32. ncbi request reprint Minimal molecular response in polycythemia vera patients treated with imatinib or interferon alpha
    Amy V Jones
    Wessex Regional Genetics Laboratory, Salisbury District Hospital, Salisbury SP2 8BJ, United Kingdom
    Blood 107:3339-41. 2006
    ..Our data indicate that, although PV patients may benefit from imatinib or rIFNalpha, molecular responses are relatively modest...
  33. ncbi request reprint Imatinib induces durable hematologic and cytogenetic responses in patients with accelerated phase chronic myeloid leukemia: results of a phase 2 study
    Moshe Talpaz
    M D Anderson Cancer Center, Houston, Texas, USA
    Blood 99:1928-37. 2002
    ..Orally administered imatinib is an effective and well-tolerated treatment for patients with CML in accelerated phase. A daily dose of 600 mg is more effective than 400 mg, with similar toxicity...
  34. ncbi request reprint Imatinib mesylate in polycythemia vera
    Jerry L Spivak
    Blood 103:3241; author reply 3241-2. 2004
  35. ncbi request reprint Characterization of murine JAK2V617F-positive myeloproliferative disease
    Thomas G P Bumm
    Center for Hematologic Malignancies, Oregon Health and Science University Cancer Institute, Portland, OR 97239, USA
    Cancer Res 66:11156-65. 2006
    ..The disease was not transplantable and prolonged observation showed normalization of blood counts in most JAK2(V617F) mice, suggesting that the mutation may not confer self-renewal capacity...
  36. ncbi request reprint Treatment of polycythemia vera with recombinant interferon
    Richard T Silver
    Department of Medicine Cornell University, New York Presbyterian Hospital, NY, USA
    Int J Hematol 76:294-5. 2002
  37. doi request reprint The revised World Health Organization diagnostic criteria for polycythemia vera, essential thrombocytosis, and primary myelofibrosis: an alternative proposal
    Jerry L Spivak
    Johns Hopkins University School of Medicine, Baltimore, MD 21205, USA
    Blood 112:231-9. 2008
  38. ncbi request reprint Primary myelofibrosis (PMF), post polycythemia vera myelofibrosis (post-PV MF), post essential thrombocythemia myelofibrosis (post-ET MF), blast phase PMF (PMF-BP): Consensus on terminology by the international working group for myelofibrosis research and
    Ruben A Mesa
    Mayo Clinic, 200 First Street SW, Rochester, MN 55905, USA
    Leuk Res 31:737-40. 2007
    ....
  39. ncbi request reprint Prognostic significance of additional cytogenetic abnormalities in newly diagnosed patients with Philadelphia chromosome-positive chronic myelogenous leukemia treated with interferon-alpha: a Cancer and Leukemia Group B study
    Sherif S Farag
    The Ohio State University Comprehensive Cancer Center, Columbus, OH 43210, USA
    Int J Oncol 25:143-51. 2004
    ..We conclude that, with the possible exception of +8, +Ph and i(17)(q10), additional chromosomal abnormalities at diagnosis are not associated with inferior outcome in Ph+ CML patients treated with IFN-alpha-based therapy...
  40. ncbi request reprint An unconventional antigen translated by a novel internal ribosome entry site elicits antitumor humoral immune reactions
    Zeyu Xiong
    Department of Pharmacology, Temple University School of Medicine, 3420 North Broad Street, Philadelphia, PA 19140, USA
    J Immunol 177:4907-16. 2006
    ..The eliciting antitumor immune response against unconventional Ag MPD6 in patients with myeloproliferative diseases suggests MPD6 as a potential target of novel immunotherapy...
  41. ncbi request reprint International Working Group (IWG) consensus criteria for treatment response in myelofibrosis with myeloid metaplasia, for the IWG for Myelofibrosis Research and Treatment (IWG-MRT)
    Ayalew Tefferi
    Mayo Clinic, 200 First Street SW, Rochester MN 55905, USA
    Blood 108:1497-503. 2006
    ..Bone marrow histologic and hematologic remissions characterize CR and CR/PR, respectively. The panel agreed that the CI response category is applicable only to patients with moderate to severe cytopenia or splenomegaly...
  42. ncbi request reprint Widespread occurrence of the JAK2 V617F mutation in chronic myeloproliferative disorders
    Amy V Jones
    Wessex Regional Genetics Laboratory, Salisbury District Hospital, Salisbury SP2 8BJ, United Kingdom
    Blood 106:2162-8. 2005
    ..We conclude that V617F is widespread in MPDs. Detection of this acquired mutation is likely to have a major impact on the way patients with MPD are diagnosed, as well as serving as an obvious target for signal transduction therapy...
  43. pmc Amplification refractory mutation system, a highly sensitive and simple polymerase chain reaction assay, for the detection of JAK2 V617F mutation in chronic myeloproliferative disorders
    Qiaofang Chen
    Department of Pathology and Laboratory Medicine, Weill Medical College of Cornell University, 1300 York Ave, New York, NY 10021, USA
    J Mol Diagn 9:272-6. 2007
    ..The assay is fast and easy to perform, and no special equipment other than thermocyclers is required. All these features make the assay readily and broadly applicable in clinical molecular diagnostic laboratories...